Vivace Therapeutics Inc. closed a $35 million series D round led by RA Capital Management, an existing investor, and including other backers already on board: Canaan Partners and Cenova Capital.

Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...

Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced the closing of a $35 million ...

Merck KGaA has patented substituted bicyclic transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TED interaction inhibitors reported to be useful for the treatment of ...